pioglitazone has been researched along with proline in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blüher, M; Lübben, G; Paschke, R | 1 |
| Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE | 1 |
| Polhill, TS; Pollock, CA; Poronnik, P; Saad, S; Stanners, SR; Zafiriou, S | 1 |
| Anthwal, S; Arenberg, DA; Keshamouni, VG; Newstead, MJ; Reddy, RC; Standiford, TJ | 1 |
1 trial(s) available for pioglitazone and proline
| Article | Year |
|---|---|
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2003 |
3 other study(ies) available for pioglitazone and proline
| Article | Year |
|---|---|
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine | 2004 |
Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
Topics: Cell Death; Cell Division; Collagen Type IV; Extracellular Matrix; Fibroblasts; Fibronectins; Gene Expression; Glucose; Humans; Hypoglycemic Agents; In Vitro Techniques; Kidney Cortex; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pioglitazone; PPAR gamma; Proline; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
Topics: Amino Acid Motifs; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL11; Chemokine CXCL5; Chemokines, CXC; Chemotaxis; Chromans; Culture Media, Conditioned; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Factor VIII; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Interleukin-8; Ligands; Lung Neoplasms; Mice; Mice, SCID; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; NF-kappa B; Pioglitazone; PPAR gamma; Proline; Thiazolidinediones; Thiocarbamates; Transfection; Troglitazone | 2005 |